At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I-II Trial of Combined PKCι and mTOR Inhibition for Patients With Advanced or Recurrent Lung Cancer (NSCLC and SCLC) Without Standard Treatment Options
In Brief
A Phase 2 clinical trial evaluating Auranofin, Sirolimus, and 2 other interventions for Extensive Stage Small Cell Lung Carcinoma and 7 related conditions. Completed, enrolled 29 participants across 2 sites.
Detailed Summary
This phase I/II trial studies the side effects and best dose of auranofin when given together with sirolimus and to see how well it works in treating patients with lung cancer that has spread or other places in the body and cannot be cured or controlled by treatment or has come back after a period of time during which the cancer could not be detected. Auranofin and sirolimus may stop or slow the growth of lung cancer.
Study Details
Timeline
Interventions
Given PO
Given PO
Correlative studies
Correlative studies